Alkermes plc (ALKS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Dublin, Ireland. The current CEO is Richard F. Pops.
ALKS has IPO date of 1991-07-16, 1,800 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $5.64B.
Alkermes plc is a biopharmaceutical company headquartered in Dublin, Ireland, that researches, develops, and commercializes pharmaceutical products to treat unmet medical needs across multiple therapeutic areas. The company's marketed portfolio includes ARISTADA and RISPERDAL CONSTA for schizophrenia, VIVITROL for alcohol use disorder and opioid dependence prevention, INVEGA SUSTENNA and related products for schizophrenia and schizoaffective disorder, and VUMERITY for relapsing forms of multiple sclerosis. Alkermes is also advancing pipeline candidates including LYBALVI, an oral atypical antipsychotic for schizophrenia and bipolar I disorder, and nemvaleukin alfa, an engineered immunotherapy designed to enhance anti-tumor immune responses. The company maintains significant collaboration agreements with Janssen Pharmaceuticals and operates across the United States, Ireland, and international markets.
